JP6891211B2 - 抗アレルギー化粧品組成物 - Google Patents
抗アレルギー化粧品組成物 Download PDFInfo
- Publication number
- JP6891211B2 JP6891211B2 JP2019075548A JP2019075548A JP6891211B2 JP 6891211 B2 JP6891211 B2 JP 6891211B2 JP 2019075548 A JP2019075548 A JP 2019075548A JP 2019075548 A JP2019075548 A JP 2019075548A JP 6891211 B2 JP6891211 B2 JP 6891211B2
- Authority
- JP
- Japan
- Prior art keywords
- amount
- allergic
- allantoin
- panthenol
- cosmetic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 59
- 239000002537 cosmetic Substances 0.000 title claims description 55
- 230000003266 anti-allergic effect Effects 0.000 title claims description 37
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 64
- 239000000284 extract Substances 0.000 claims description 37
- 235000013339 cereals Nutrition 0.000 claims description 33
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 32
- 229960000458 allantoin Drugs 0.000 claims description 32
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 29
- 235000004866 D-panthenol Nutrition 0.000 claims description 21
- 239000011703 D-panthenol Substances 0.000 claims description 21
- 229960003949 dexpanthenol Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 241000209140 Triticum Species 0.000 claims description 12
- 235000021307 Triticum Nutrition 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 3
- SNPLKNRPJHDVJA-SSDOTTSWSA-N (2s)-2,4-dihydroxy-n-(3-hydroxypropyl)-3,3-dimethylbutanamide Chemical compound OCC(C)(C)[C@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-SSDOTTSWSA-N 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 210000003630 histaminocyte Anatomy 0.000 description 28
- 239000007921 spray Substances 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 19
- -1 polydimethylsiloxane Polymers 0.000 description 15
- 230000002757 inflammatory effect Effects 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000252212 Danio rerio Species 0.000 description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 206010012442 Dermatitis contact Diseases 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 229940101267 panthenol Drugs 0.000 description 7
- 235000020957 pantothenol Nutrition 0.000 description 7
- 239000011619 pantothenol Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000001624 sedative effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 208000002029 allergic contact dermatitis Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 208000001875 irritant dermatitis Diseases 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000004006 olive oil Substances 0.000 description 6
- 235000008390 olive oil Nutrition 0.000 description 6
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 5
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000932 sedative agent Substances 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000001400 Tryptase Human genes 0.000 description 4
- 108060005989 Tryptase Proteins 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003237 betaine Drugs 0.000 description 4
- 230000002951 depilatory effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229930182478 glucoside Natural products 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 244000274847 Betula papyrifera Species 0.000 description 3
- 235000009113 Betula papyrifera Nutrition 0.000 description 3
- 235000009109 Betula pendula Nutrition 0.000 description 3
- 235000010928 Betula populifolia Nutrition 0.000 description 3
- 235000002992 Betula pubescens Nutrition 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
- 241001135917 Vitellaria paradoxa Species 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 229960004958 ketotifen Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 229940100460 peg-100 stearate Drugs 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 229940057910 shea butter Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- KZRXPHCVIMWWDS-AWEZNQCLSA-N (4S)-4-amino-5-dodecanoyloxy-5-oxopentanoic acid Chemical compound CCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC(O)=O KZRXPHCVIMWWDS-AWEZNQCLSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920002055 compound 48/80 Polymers 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000000495 immunoinflammatory effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940071085 lauroyl glutamate Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- WQKLGQXWHKQTPO-UXRZSMILSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol;2-(2-hydroxypropoxy)propan-1-ol Chemical compound CC(O)COC(C)CO.CC(O)COC(C)CO.CC(O)COC(C)CO.CC(O)COC(C)CO.CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WQKLGQXWHKQTPO-UXRZSMILSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- IDUUXROOZBOOPH-QHHAFSJGSA-N 2-{[(2E)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1NC(=O)\C=C\C1=CC=C(O)C(O)=C1 IDUUXROOZBOOPH-QHHAFSJGSA-N 0.000 description 1
- QRTADFOPPOKFDH-UHFFFAOYSA-N 20,21-dihydroxyhenicosanoic acid Chemical compound OCC(O)CCCCCCCCCCCCCCCCCCC(O)=O QRTADFOPPOKFDH-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- YHSRVRQTESQERG-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;hexadecanoic acid Chemical compound CC1=NC=C(CO)C(CO)=C1O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O YHSRVRQTESQERG-UHFFFAOYSA-N 0.000 description 1
- IMCSHHYECBJTOO-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol;octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O.CC1=NC=C(CO)C(CO)=C1O IMCSHHYECBJTOO-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229930190481 Avenanthramide Natural products 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241001548492 Coreus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 description 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- TZDOBCZHGBGJLS-KTKRTIGZSA-N MG(0:0/22:1(13Z)/0:0) Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OC(CO)CO TZDOBCZHGBGJLS-KTKRTIGZSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- DEOKFPFLXFNAON-UHFFFAOYSA-N N-α-Benzoyl-DL-arginine 4-nitroanilide hydrochloride Chemical compound Cl.C=1C=C([N+]([O-])=O)C=CC=1NC(=O)C(CCCN=C(N)N)NC(=O)C1=CC=CC=C1 DEOKFPFLXFNAON-UHFFFAOYSA-N 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102100023170 Nuclear receptor subfamily 1 group D member 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 101000611641 Rattus norvegicus Protein phosphatase 1 regulatory subunit 15A Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- DRRMRHKHTQRWMB-UHFFFAOYSA-N [3-(2-ethylhexanoyloxy)-2,2-bis(2-ethylhexanoyloxymethyl)propyl] 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(COC(=O)C(CC)CCCC)(COC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DRRMRHKHTQRWMB-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940099417 ceramide 2 Drugs 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000010487 meadowfoam seed oil Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229940061570 polyglyceryl-10 stearate Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229940078492 ppg-17 Drugs 0.000 description 1
- 229940116393 ppg-20 methyl glucose ether Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/445—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof aromatic, i.e. the carboxylic acid directly linked to the aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
一態様では、本発明は、肥満細胞の保護、ひいては皮膚に対する抗アレルギーに対してD−パンテノール、アラントインおよびカラスムギ穀粒エキスの組合せを使用することに関する。
(1)水を80℃に加熱し、アラントイン、グリセリン、パンテノールおよびベタインを順次加え、混合し、撹拌し、均一に溶解させる。
(2)混合物を40℃に冷却し、カラスムギ穀粒エキスを加え、排出する。
得られたスプレーAは淡黄色透明液体であった。
この例では、上記と同様の手順を用いて、以下の成分を有する対照スプレーB、C、DおよびEを調製し、対照スプレーにはいずれもパンテノール、アラントインおよびカラスムギ穀粒エキスの組合せを含めなかった。得られたスプレーBは無色透明の液体であり、スプレーC、DおよびEは淡黄色透明液体であった。
以下の方法に従って、細胞のアレルギー反応に対する調製済みスプレーA〜Eの効果を試験した。
化合物48/80は肥満細胞脱顆粒を誘発するためのツール薬物(tool drug)であり、その機序は、肥満細胞膜に作用し、細胞内カルシウムイオンの増加を誘発してセカンドメッセンジャーcAMPおよびcGMPの量を変化させ、肥満細胞脱顆粒およびヒスタミン放出をもたらすことである。
浙江省医学科学院の動物センターより、RBL−2H3細胞系を得た。試験試料には、上記で調製した5つのスプレーA〜Eを含めた。試薬には、ウシ胎児血清、RPM1640培地、Tyrode塩(主に塩化ナトリウム、ホスファート、塩化カルシウム、グルコースなどから構成される)、化合物48/80およびヒスタミンElisaキットを含めた。
以下の方法に従って、ゼブラフィッシュ幼生の肥満細胞に対する上記で調製したスプレーA〜Eの保護効果を測定した。
物質P(SP、分子式C63H98N18O13S)は、タキキニン神経ペプチドファミリーに属する神経ペプチドである。SPは、肥満細胞脱顆粒を誘発し、ヒスタミン、トリプターゼおよび他のメディエーターを急速に放出させ、肥満細胞によって引き起こされる一連の免疫炎症反応を直接媒介することができる。
上記で調製したスプレーA〜E、および陽性対照として60μg/mlのケトチフェンを使用。
野生型ゼブラフィッシュ胚を採取し、E3緩衝液(5mM NaCl、0.17mM KCl、0.33mM CaCl2、0.33mM MgSO4を含み、最終容積まで水を添加した幼生培養用)を用いて、5dpf(受精後の日数)まで28.5℃のインキュベーター内で培養した。緩衝液を毎日交換し、1ウェル当たり10尾の群、1群当たり4つの二重ウェルで、5dpfのゼブラフィッシュを48ウェル細胞培養プレートに無作為に移した。以下のように分類した。
モデル群Msp:純水+15μg/ml SP
陽性群Tsp:60μg/mlケトチフェン+15μg/ml SP
試験対象の試料群XSP:試験対象のスプレー試料+15μg/ml SP
ここで、陽性薬物ケトチフェンは、DMSOを加えて母液に配合し、−20℃で保存し、実験に使用する際に純水を加えて60μg/mlの液体に配合した。
試験対象の試料の肥満細胞の保護率=[(Msp−Msp.bg)−(RO−RObg)]−[(Xsp−Xsp.bg)−(X−Xbg)]/(Msp−Msp.bg)−(RO−RObg)×100%
式中、
Msp−Msp.bgは、SP誘発脱顆粒群(すなわちモデル群)の吸光度から、その対応するバックグラウンド対照群(ゼブラフィッシュ幼生なし)の吸光度を引いたものを表し、
RO−RObgは、SPを含まない超清浄水群(すなわちモデル群の陰性対照群)の吸光度から、その対応するバックグラウンド対照群の吸光度を引いたものを表し、
Xsp−Xsp.bgは、SP誘発脱顆粒の試料群の吸光度から、その対応するバックグラウンド対照群の吸光度を引いたものを表し、
X−Xbgは、SPを含まない試料群の吸光度から、その対応するバックグラウンド対照群の吸光度を引いたものを表す。
以下の方法に従って、マウスモデルに対するスプレーA〜Eの抗炎症効果を測定した。
刺激性接触皮膚炎(ICD)は、強い刺激(強い酸およびアルカリなど)または接触原自体の毒性によって引き起こされる。その組織病理学的症状には、血管拡張、血漿浸出、および炎症反応を引き起こすための血液中の白血球の局所組織への浸潤が挙げられる。ICDは非免疫性炎症反応であると一般に考えられている。この実験モデルでは、化学試薬を使用してマウスの腹部の裸の皮膚を刺激し(10%ドデシル硫酸ナトリウム、SDS)、皮膚バリアの損傷および皮膚の局所炎症反応の悪化を引き起こした。炎症因子指標を使用して、後の抗炎症効果評価実験のためにモデルが確立されたかどうかを決定した。
10%ドデシル硫酸ナトリウム溶液(SDS)、1%ヒドロコルチゾン軟膏、脱毛ペースト。
体重に応じて、ICRマウスを、正常群、モデル群、陽性群およびスプレー試験群を含む各群12匹に無作為に割り付けた。モデル化の1日前に、各群のマウスを脱毛ペーストを用いて処置して、マウスの腹部の約2×2cmの面積の毛を除去した。モデル群、陽性群および試験群:モデル化の日に、50μLの10%ドデシル硫酸ナトリウム溶液をピペットで取り、5日間にわたりマウスの裸の皮膚に均一に適用した。モデル化後:陽性群は1%ヒドロコルチゾン軟膏を用いて1日3回2日間連続して治療した。モデル群は治療しなかった。陽性群と同じ方法で、各試験群に溶液を投与した。正常群のマウスを同じ方法により処置して腹部の毛を除去し、7日間給餌し、比較した。実験7日目に、実験用マウスの各群の皮膚状態を観察し、マウスの血清を採取して、炎症因子IL−1aの量を決定した。
急性バリア機能不全は、MyD経路を活性化し、MyD経路の下流の炎症因子IL−1aの合成を増加させる可能性があり、これは皮膚の炎症状態では繰り返し観察される。この実験では、10%SDSによって引き起こされた刺激性皮膚炎の実現性を、モデル群、陽性群および正常群を比較することによって観察し、陽性薬物ヒドロコルチゾンを用いた治療によって試験した。
化粧品アレルギーは、一般に化粧品アレルギー性接触皮膚炎と呼ばれ、化粧品性皮膚炎の30.0〜46.2%にも達する。化粧品アレルギー性接触皮膚炎は、刺激性皮膚炎よりも重症であることが多く、交差アレルギー反応が起こり、治療は比較的困難である。したがって、2,4−ジニトロフルオロベンゼン(DNFB)を用いてマウスを感作および刺激して、アレルギー性接触皮膚炎モデル(ACD)を確立し、陽性対照として1%ヒドロコルチゾン軟膏を投与し、試験群を対象に有効性評価実験を行った。
DNFBアセトン/オリーブ油(4:1)溶液、1%ヒドロコルチゾン軟膏、脱毛ペースト。
体重に応じて、ICRマウスを、正常群、モデル群、陽性群およびスプレー試験群を含む各群12匹に無作為に割り付けた。モデル化の1日前に、各群のマウスを脱毛ペーストを用いて処置して、マウスの腹部の約2×2cmの面積の毛を除去した。モデル化の日に、5%DNFBアセトン/オリーブ油溶液100μLをマウスの裸の皮膚に2日間連続して均一に適用することによって、モデル群、陽性群および試験群のマウスを感作した。5日目に、30μL/耳の1%DNFBアセトン/オリーブ油溶液をマウスの両耳の耳介表面の内側および外側に均一に適用することによってマウスを刺激して、アレルギー性接触皮膚炎モデルを確立した。正常群のマウスは、腹部および耳部にアセトン/オリーブ油(4:1)溶液を用いて処置した。
耳厚指標:
殺処分後、マウスの耳の厚みを測定し、両耳の平均厚みを求めた。
殺処分後、穿孔器(Deli、直径8mm)によって各マウスの耳を採取し、総重量を秤量した。
マウスの血清を採取し、ELISAキットにより、マウスの耳組織内の炎症因子IFN−γの量を検出した。
アレルギー性疾患の発症機序では、Th1/Th2の不均衡は重要な因果関係または開始因子として現れる。通常、Th1細胞およびTh2細胞は動的平衡状態にあり、それら自身のサイトカイン(IFN−rなどのTh1サイトカイン、IL−4などのTh2サイトカイン)を分泌することによって互いに阻害する。Th1細胞はIFN−Y、TNF−α、IL−2などを産生し、接触アレルギーを引き起こす。Th2細胞はIL−4、IL−5、IL−10、IL−13などを産生し、接触過敏症を抑制する。
上記の結果は、本発明の範囲内のスプレーAの抗炎症効果が、あらゆる指標でスプレーB〜Eのそれよりも有意に優れていたことを実証しており、カラスムギ穀粒エキス、パンテノールおよびアラントインの組合せが、マウスの接触皮膚炎の鎮静に対して相乗効果を有していたことを示す。
1.シラカバ樹液を80℃に加熱し、クエン酸、パンテノール、アラントイン、3部のグリセリン、ヒドロキシ安息香酸メチル、ブタンジオール、ペンタンジオールおよびベタインを順次加え、混合し、撹拌し、均一に溶解させた。
2.ラウロイルグルタミン酸ジ(フィトステリル/オクチルドデシル)、トリ2−エチルヘキサン酸グリセリル、2部のグリセリン、グリセレス−26およびPEG−60水添ヒマシ油を80℃に加熱し、均一に撹拌し、次いで工程1で得られた混合物に加えた。
3.生成物を40℃に冷却し、カラスムギ穀粒エキスおよびフェノキシエタノールを順次加え、アルギニンを用いてpHを調節し、生成物を排出した。
1.水相:水、グリセリン、パンテノール、アラントイン、加水分解ヒアルロン酸ナトリウム、ジプロピレングリコール、キサンタンガム、カルボマーおよびヒドロキシ安息香酸メチルを混合し、80℃に加熱し、撹拌し、均一に溶解させた。
2.油相:セチルアルコール、ステアリン酸グリセリル/ステアリン酸PEG−100、トリ(カプリル酸/カプリン酸)グリセリル、トリ2−エチルヘキサン酸グリセリルおよびシアバター。原料を80℃に加熱し、撹拌し、均一に溶解させた。
3.水相と油相とを混合し、5分間ホモ乳化し、乳化が完了したら、水に溶解させたアルギニンを加え、15分間撹拌し、40℃に冷却し、カラスムギ穀粒エキスおよびフェノキシエタノールを順次加えた。
1.水相:水、グリセリン、パンテノール、アラントイン、加水分解ヒアルロン酸ナトリウム、グリセレス−26、キサンタンガム、カルボマーおよびヒドロキシ安息香酸メチル。
2.油相:セチルアルコール、カプリル酸エステル/カプリン酸エステル、ペンタエリスリトールテトラ(2−エチルヘキサノエート)、ステアリン酸グリセリル/ステアリン酸PEG−100、シアバター、ポリジメチルシロキサン、ヒドロキシ安息香酸プロピル。原料を80℃に加熱し、撹拌し、均一に溶解させた。
3.水相と油相とを混合し、5分間ホモ乳化し、乳化が完了したら、水に溶解させたアルギニンを加え、15分間撹拌し、40℃に冷却し、カラスムギ穀粒エキス、フェノキシエタノールおよびカプリリルグリコールを順次加えた。
本発明に包含され得る諸態様は、以下のとおり要約される。
[態様1]
肥満細胞の保護、ひいては抗アレルギーに対するD−パンテノール、アラントインおよびカラスムギ穀粒エキスの組合せの使用。
[態様2]
D−パンテノール、アラントインおよびカラスムギ穀粒エキスの組合せならびに化粧品に通常使用される成分を含む抗アレルギー化粧品組成物。
[態様3]
前記化粧品組成物の総重量に基づいて、D−パンテノールの量が約0.02〜3%であり、アラントインの量が約0.01〜1.5%であり、カラスムギ穀粒エキスの量が約0.2〜5%である、上記態様2に記載の化粧品組成物。
[態様4]
D−パンテノールの量が約0.05〜2%であり、アラントインの量が約0.03〜1%であり、カラスムギ穀粒エキスの量が約0.5〜4%である、上記態様3に記載の化粧品組成物。
[態様5]
化粧品組成物を皮膚に適用することを含む抗アレルギー化粧方法であって、前記化粧品組成物が、D−パンテノール、アラントインおよびカラスムギ穀粒エキスの組合せならびに化粧品組成物に通常使用される成分を含む、抗アレルギー化粧方法。
[態様6]
前記化粧品組成物の総重量に基づいて、D−パンテノールの量が約0.02〜3%であり、アラントインの量が約0.01〜1.5%であり、カラスムギ穀粒エキスの量が約0.2〜5%である、上記態様5に記載の化粧方法。
[態様7]
D−パンテノールの量が約0.05〜2%であり、アラントインの量が約0.03〜1%であり、カラスムギ穀粒エキスの量が約0.5〜4%である、上記態様6に記載の化粧方法。
Claims (6)
- 抗アレルギー皮膚化粧品組成物の調製における、D−パンテノール、アラントインおよびカラスムギ穀粒エキスの組合せの使用であって、
前記抗アレルギー皮膚化粧品組成物の総重量に基づいて、抗アレルギー皮膚化粧品組成物中でのD−パンテノールの量が0.02〜3%であり、アラントインの量が0.01〜1.5%であり、カラスムギ穀粒エキスの量が0.2〜5%である使用。 - D−パンテノールの量が0.05〜2%であり、アラントインの量が0.03〜1%であり、カラスムギ穀粒エキスの量が0.5〜4%である、請求項1に記載の使用。
- 化粧品組成物を皮膚に適用することを含む非治療的な抗アレルギー化粧方法であって、前記化粧品組成物が、D−パンテノール、アラントインおよびカラスムギ穀粒エキスの組合せならびに化粧品組成物に通常使用される成分を含む、非治療的な抗アレルギー化粧方法であって、
前記化粧品組成物の総重量に基づいて、D−パンテノールの量が0.02〜3%であり、アラントインの量が0.01〜1.5%であり、カラスムギ穀粒エキスの量が0.2〜5%である非治療的な化粧方法。 - D−パンテノールの量が0.05〜2%であり、アラントインの量が0.03〜1%であり、カラスムギ穀粒エキスの量が0.5〜4%である、請求項3に記載の非治療的な化粧方法。
- 抗アレルギー皮膚化粧品組成物用の抗アレルギー組み合わせパッケージであって、D−パンテノール、アラントインおよびカラスムギ穀粒エキスの組み合わせからなる、抗アレルギー組み合わせパッケージであって、
前記抗アレルギー皮膚化粧品組成物の総重量に基づいて、抗アレルギー皮膚化粧品組成物中でのD−パンテノールの量が0.02〜3%であり、アラントインの量が0.01〜1.5%であり、カラスムギ穀粒エキスの量が0.2〜5%である抗アレルギー組み合わせパッケージ。 - D−パンテノールの量が0.05〜2%であり、アラントインの量が0.03〜1%であり、カラスムギ穀粒エキスの量が0.5〜4%である、請求項5に記載の抗アレルギー組み合わせパッケージ。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810863822.0 | 2018-08-01 | ||
CN201810863822.0A CN108670878B (zh) | 2018-08-01 | 2018-08-01 | 抗皮肤过敏的化妆品组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020019762A JP2020019762A (ja) | 2020-02-06 |
JP6891211B2 true JP6891211B2 (ja) | 2021-06-18 |
Family
ID=63815109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019075548A Active JP6891211B2 (ja) | 2018-08-01 | 2019-04-11 | 抗アレルギー化粧品組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20210353521A1 (ja) |
EP (1) | EP3628305A4 (ja) |
JP (1) | JP6891211B2 (ja) |
KR (1) | KR102360658B1 (ja) |
CN (1) | CN108670878B (ja) |
WO (1) | WO2020024598A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110090190B (zh) * | 2019-05-22 | 2022-04-15 | 中山爱护日用品有限公司 | 一种婴童植物舒缓清凉液及其制备方法 |
CN111973471A (zh) * | 2019-05-24 | 2020-11-24 | 西安博鸿生物技术有限公司 | 化妆品组合物 |
CN110732002A (zh) * | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有增强的抗湿疹功效的皮肤外用组合物 |
CN110227088B (zh) * | 2019-07-30 | 2021-11-19 | 养生堂(安吉)化妆品有限公司 | 具有止痒功效的皮肤外用组合物 |
CN110731991A (zh) | 2019-07-30 | 2020-01-31 | 浙江养生堂天然药物研究所有限公司 | 具有祛痘功效的皮肤外用组合物 |
MX2022010949A (es) * | 2020-03-06 | 2022-10-18 | Symrise Ag | Composiciones de avenantramida con solubilidad mejorada que comprenden 4-hidroxifenona. |
CN111297713A (zh) * | 2020-04-15 | 2020-06-19 | 斑敏痘(广东)皮肤研究院 | 抗敏修复护肤制剂 |
CN112033944B (zh) * | 2020-08-26 | 2023-03-28 | 南京新环检测科技有限公司 | 一种评价化妆品对皮肤刺激性的方法 |
CN114712260B (zh) * | 2022-04-07 | 2023-08-01 | 上海新高姿化妆品有限公司 | 具有舒缓修护美白功效的皮肤外用组合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1893161B1 (en) * | 2005-06-14 | 2015-08-26 | Symrise AG | Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching |
KR20080002279A (ko) * | 2006-06-30 | 2008-01-04 | (주)아모레퍼시픽 | 아토피 증상 개선의 효과가 있는 입술용 화장료 조성물 |
CN105708757A (zh) * | 2016-02-17 | 2016-06-29 | 佛山市芊茹化妆品有限公司 | 一种抗过敏微乳液 |
CN105769707A (zh) * | 2016-04-22 | 2016-07-20 | 欧标(广州)化妆品有限公司 | 一种用于祛痘的组合物及其在化妆品中的应用 |
CN107184411B (zh) * | 2017-04-21 | 2019-02-22 | 韩后化妆品股份有限公司 | 一种复合水嫩因子、化妆品及化妆品的制备方法 |
-
2018
- 2018-08-01 CN CN201810863822.0A patent/CN108670878B/zh active Active
-
2019
- 2019-03-25 EP EP19730104.7A patent/EP3628305A4/en active Pending
- 2019-03-25 KR KR1020197022473A patent/KR102360658B1/ko active IP Right Grant
- 2019-03-25 US US16/489,069 patent/US20210353521A1/en not_active Abandoned
- 2019-03-25 WO PCT/CN2019/079521 patent/WO2020024598A1/zh unknown
- 2019-04-11 JP JP2019075548A patent/JP6891211B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN108670878A (zh) | 2018-10-19 |
JP2020019762A (ja) | 2020-02-06 |
CN108670878B (zh) | 2021-06-04 |
WO2020024598A1 (zh) | 2020-02-06 |
KR20200015443A (ko) | 2020-02-12 |
US20210353521A1 (en) | 2021-11-18 |
EP3628305A1 (en) | 2020-04-01 |
EP3628305A4 (en) | 2020-12-02 |
KR102360658B1 (ko) | 2022-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6891211B2 (ja) | 抗アレルギー化粧品組成物 | |
US6866856B2 (en) | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis | |
PL188708B1 (pl) | Zastosowanie, w kompozycji, wyciągu z przynajmniej jednej rośliny z rodziny Labiatae (wargowych) z rodzaju Rosmarinus uprawianej in vitro i kompozycja zawierająca ten wyciąg | |
RU2442563C2 (ru) | Композиции, содержащие белки для переноса/рециркуляции структурно модифицированных липидов, и их применение | |
US20070172431A1 (en) | Methods, systems and compositions for skin care | |
KR20220136979A (ko) | 콜히친을 포함하는 알레르기성 피부 질환 또는 피부 소양증 치료용 조성물 | |
KR101136742B1 (ko) | 연산호류 추출물 및 그것의 용도 | |
JP4869751B2 (ja) | サンバーンセル形成抑制剤及びdna損傷修復促進剤 | |
DK2306999T3 (en) | Compositions for the treatment of rosacea comprising chitosan and a dicarboxylsyreamid | |
WO2021017448A1 (zh) | 具有止痒功效的皮肤外用组合物 | |
JPH06305932A (ja) | 皮膚外用剤 | |
FR2984129A1 (fr) | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu | |
FR3034667A1 (fr) | Composition cosmetique et/ou dermatologique contre l'acne | |
DE102007024679A1 (de) | Verwendung von kosmetisch aktiven Wirkstoffen zum Schützen von FGF-2 | |
JP2018145106A (ja) | 皮膚外用組成物 | |
CN110547975B (zh) | 包含表松脂酚的化妆材料组合物 | |
EP4197534A1 (en) | Reelin/vegf-c production/activation promoter and skin external composition using the same | |
EP4186498A1 (en) | Reelin/vegf-c production/activation promoter and skin external composition using the same | |
JP2001261567A (ja) | 皮膚外用剤 | |
KR20210070777A (ko) | 피부장벽 강화용 조성물 | |
KR20230095381A (ko) | 다래열매추출물, 다래꽃추출물 및 다래줄기추출물을 포함하는 화장료조성물 및 그 제조방법 | |
KR20230067034A (ko) | 항산화, 미백, 항염증, 피부보호 등의 기능을 갖는 락토페린 유도체 제조방법 및 이를 포함하는 피부 치료용 연고 및 화장품 조성물 | |
KR20240077320A (ko) | 피부 보습, 피부 가려움증 개선 및 피부장벽 강화용 화장료 조성물 및 이를 포함하는 피부 케어 제품 | |
KR101434446B1 (ko) | 참그물바탕말을 이용한 피부 외용제 조성물 | |
KR20240015803A (ko) | 수크랄페이트를 포함하는 피부 재생용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200603 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200825 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210519 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210526 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6891211 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |